RCKT(Rocket Pharmaceuticals, Inc.) · 财务报表

RCKT(Rocket Pharmaceuticals, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$0$0$0$0$0
毛利润—————
营业利润−$167.25M−$224.34M−$259.66M−$273.20M−$231.75M
净利润−$169.07M−$221.86M−$245.59M−$258.75M−$223.12M
经营现金流−$121.16M−$178.14M−$194.92M−$209.72M−$190.01M
自由现金流−$128.78M−$186.50M−$211.35M−$215.59M−$190.45M
摊薄每股收益$-2.67$-3.26$-2.92$-2.73$-2.01

Rocket Pharmaceuticals, Inc. RCKT